“…The PrP promoter line has been successfully used in several studies of various diseases, including prion diseases (Safar et al, 2005;Tremblay et al, 1998), Parkinson's disease (Nuber et al, 2008), analysis of alcohol consumption (Choi et al, 2002), spinocerebellar ataxia type 3 (Boy et al, 2009), and neurofilament transport (Millecamps et al, 2007). The CamKII promoter line has been used for the investigation of synaptic plasticity, learning and memory consolidation (Bukalo et al, 2004;Limback-Stokin et al, 2004;Mayford et al, 1997;Wood et al, 2005), neurodevelopmental disorders (Alvarez-Saavedra et al, 2007;Jerecic et al, 2001), and for the generation of transgenic mouse models for Alzheimer's disease (Jankowsky et al, 2005), Huntington's disease (Yamamoto et al, 2000), Parkinson's disease (Nuber et al, 2008), neocortical degeneration (Muyllaert et al, 2008), schizophrenia (Pletnikov et al, 2008), and neurofibromatosis (Saito et al, 2007).…”